A phase 2/3 study might show whether teliso-A can do better than teliso-V.

First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.

PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.

Roche dumps another partnered asset.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.